Nov 04, 2021 9:37am EDT Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
Nov 01, 2021 4:05pm EDT Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
Nov 01, 2021 9:15am EDT Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships
Oct 27, 2021 9:05am EDT Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations
Oct 25, 2021 4:57pm EDT Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET
Sep 30, 2021 9:30am EDT Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
Sep 28, 2021 9:20am EDT Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer
Sep 22, 2021 9:00am EDT Lantern Pharma CEO to Present at the Benzinga Healthcare Small Cap Conference on September 29th
Sep 07, 2021 9:02am EDT Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September
Sep 02, 2021 8:59am EDT Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives
